Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
14 search results for:

Alpelisib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 04-10-2023 | Adverse events | News | Article

    High incidence of alpelisib‐associated hyperglycemia in routine care

    A retrospective analysis has found a significantly higher incidence of hyperglycemia among breast cancer patients treated with alpelisib in standard care than on clinical trials.

    Author:
    Shreeya Nanda
    Published in:
    Cancer 2023; doi:10.1002/cncr.34928
  2. 22-08-2022 | Breast cancer | News | Article

    Alpelisib ‘a likely cause’ of colitis

    US researchers have described a series of cases of colitis in patients receiving the PI3K inhibitor alpelisib.

    Author:
    Shreeya Nanda
    Published in:
    JAMA Oncol 2022; doi:10.1001/jamaoncol.2022.3249
  3. play
    22-09-2020 | ESMO 2020 | Conference coverage | Video

    OS results from SOLAR-1 trial of alpelisib reported

    Fabrice André presents the overall survival data from the SOLAR-1 trial of alpelisib in patients with hormone receptor-positive, HER2-negative, advanced breast cancer, and outlines the next steps for the further development of alpelisib and other PI3K inhibitors in this setting.

  4. 02-06-2020 | ASCO 2020 | News | Article

    BYLieve suggests alpelisib–fulvestrant benefit after progression on CDK inhibitors

    The combination of alpelisib and fulvestrant could be a promising option for patients with PIK3CA -mutated, hormone receptor-positive, HER2-negative advanced breast cancer who have progressed on prior CDK4/6 inhibitor and aromatase inhibitor treatment, indicate trial data.

    Author:
    Shreeya Nanda
    Published in:
    2020 ASCO Annual Meeting; 29–31 May
  5. 22-06-2020 | EMA | News | Article
    approvalsWatch

    Alpelisib positive opinion adopted for advanced PIK3CA-mutated breast cancer

    medwireNews : The EMA has adopted a positive opinion for the use of alpelisib alongside fulvestrant in patients with locally advanced and metastatic breast cancer with an activating PIK3CA mutation.

    Author:
    Lynda Williams
  6. play
    24-10-2018 | Breast cancer | ESMO 2018 | Video

    Evaluating alpelisib addition to standard of care in SOLAR-1

    We speak to Fabrice André about the SOLAR-1 trial and its impact on the care of patients with hormone receptor-positive, HER2-negative advanced breast cancer (5:19).

  7. 21-10-2018 | Breast cancer | News | Article

    Adding alpelisib to fulvestrant boosts PI3KCA-mutant metastatic breast cancer PFS

    Patients with hormone receptor-positive, HER2-negative metastatic breast cancer harboring PI3KCA mutations derive a significant progression-free survival benefit when fulvestrant is supplemented with the PI3K inhibitor alpelisib, phase III data show.

    Published in:
    ESMO 2018; Munich, Germany; 19–23 October
  8. 18-10-2022 | PI3K inhibitors | News | Article

    Meta-analysis reveals high risk for cutaneous AEs with PI3K inhibitors

    The meta-analysis included 16 phase 2 or 3 RCTs that evaluated the efficacy of PI3K inhibitors – such as alpelisib, idelalisib, pictilisib, sonolisib, and taselisib – in patients with malignant conditions and reported on cutaneous AEs.

    Author:
    Shreeya Nanda
    Published in:
    JAMA Oncol 2022; doi:10.1001/jamaoncol.2022.4327
  9. 08-12-2021 | SABCS 2021 | Conference coverage | Article

    Appropriate framework must guide targeted therapy for metastatic breast cancer

    Targeted therapies included vistusertib (targeting mTOR alterations), AZD4547 ( FGFR ), capivasertib ( AKT ), sapitinib ( HER2 or EGFR ), selumetinib ( MEK ), vandetanib ( VEGF or EGFR ), bicalutamide (androgen receptor), olaparib ( PARP ), and alpelisib ( PIK3CA ).

    Author:
    Laura Cowen
    Published in:
    SABCS 2021; 7–10 December
  10. play
    02-06-2020 | ASCO 2020 | Conference coverage | Video

    Expert highlights: Breast cancer at ASCO 2020

    Bora Lim rounds up the breast cancer studies that caught her attention at the virtual 2020 ASCO Annual Meeting, including the MONALEESA pooled ctDNA analysis and the BYLieve trial (7:04).

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.